Loading clinical trials...
Loading clinical trials...
Adding Metformin to Insulin in Controlling Pregestational and Gestational Diabetes Mellitus and Improving Neonatal Outcome Regarding Birth Weight
The purpose of the study to prove benefits of adding metformin to insulin for controlling presentational and gestational diabetes mellitus and improving neonatal outcome.
The current study was conducted at Ain Shams university maternity hospital during the period between June 2016 to December 2016. All patients were subjected to: 1. History taking: 2. General and Abdominal Examination: With particular emphasis on : * Body mass index * Blood pressure. * Fundal height . * Estimated fetal weight . 3. Insulin and metformin doses : Insulin dose: 0.7 IU/Kg (at the second trimester of pregnancy). 0.8 IU/Kg (at the third trimester of pregnancy). Insulin dose was raised at a rate of 1 IU for every 10 mg/dl higher than the target blood glucose concentration. Metformin dose : Oral metformin at a dose of 1500 mg divided into three doses, were taken with meals, in addition to insulin. If the target blood glucose concentrations were not attained, the dose of metformin was raised to 2000 mg per day. 4. Investigations: Fasting and two hours postprandial blood glucose levels were measured in two groups of pregnant women: 1. Group I: pregnant women who received oral metformin in addition to insulin therapy. 2. Group II: pregnant women who received insulin therapy only.
Age
20 - 35 years
Sex
FEMALE
Healthy Volunteers
Yes
Start Date
June 1, 2016
Primary Completion Date
December 1, 2016
Completion Date
December 1, 2016
Last Updated
June 14, 2017
62
ACTUAL participants
Insulin Mixtard
DRUG
Metformin
DRUG
Lead Sponsor
Ain Shams University
NCT06948825
NCT06643351
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions